Mirati Therapeutics Inc (DELISTED) (MRTX:DL)
58.70
0.00 (0.00%)
USD |
NASDAQ |
Jan 23, 16:00
Price Chart
Key Stats
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States. |
| URL | https://www.mirati.com |
| Investor Relations URL | https://ir.mirati.com |
| HQ State/Province | California |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 28, 2024 (est.) |
| Last Earnings Release | Nov. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States. |
| URL | https://www.mirati.com |
| Investor Relations URL | https://ir.mirati.com |
| HQ State/Province | California |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 28, 2024 (est.) |
| Last Earnings Release | Nov. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |